Clinical Trials on Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia in Japan

Total 100 results

Novartis Pharmaceuticals

Completed

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Japan
Pfizer

Completed

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Spain, Canada, Austria, Czechia, France, Hungary, Italy, Japan, Mexico, Poland, United Kingdom
Takeda
Takeda Development Center Americas, Inc.

Active, not recruiting

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)

Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Myelodysplastic Syndrome

Australia, United States, Canada, Spain, Belgium, France, Czechia, Italy, Korea, Republic of, Israel, Brazil, China, Germany, Turkey, Japan, Greece, Poland, United Kingdom, Russian Federation, Mexico
Boehringer Ingelheim

Completed

Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

Japan
Celgene Corporation

Terminated

Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Multiple Myeloma | Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Non-Hodgkin Lymphoma

Japan
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more
Celgene

Completed

A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan
OncoVerity, Inc.
Janssen Pharmaceutical K.K.; argenx

Completed

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Leukemia, Myeloid, Acute

Japan
AstraZeneca

Completed

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

Japan
Keio University

Completed

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

Japan
AbbVie

Terminated

Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States, Australia, Germany, Israel, Italy, Japan, Spain
Astellas Pharma Global Development, Inc.

Completed

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML)

United States, Japan
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

AML and High Risk MDS

Germany, Italy, France, Netherlands, United States, Australia, Japan
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

Leukemia, Myeloid, Acute | Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS)

Spain, United States, France, Korea, Republic of, Taiwan, Australia, Canada, Germany, China, Italy, Austria, Czechia, Poland, Japan, United Kingdom, Russian Federation, Netherlands, Brazil, Israel, Mexico
Astex Pharmaceuticals, Inc.

Completed

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

United States, Spain, Korea, Republic of, France, Denmark, Canada, Germany, Italy, Czechia, United Kingdom, Poland, Japan, Sweden, Belgium
Millennium Pharmaceuticals, Inc.

Completed

A Study of Pevonedistat in Adult East Asian Participants

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan, Taiwan, Korea, Republic of
Osaka University
Japan Agency for Medical Research and Development

Recruiting

Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.

Acute Myeloid Leukemia in Remission

Japan
Genzyme, a Sanofi Company

Completed

A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)

Acute Myelogenous Leukemia

Japan
Astellas Pharma Inc

Completed

Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Phase I Study of OPB-51602 in Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia

Japan
Kanto CML Study Group

Unknown

Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan (D-First)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Myelogenous Leukemia, Chronic, Chronic Phase

Japan
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | AML | Myelodysplastic Syndrome | MDS | Non-Hodgkins Lymphoma | NHL

United States, Australia, Italy, France, Greece, Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients

Acute Myeloid Leukemia

Japan
Boehringer Ingelheim

Completed

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)

Acute Myeloid Leukemia

Japan
Sumitomo Pharma Co., Ltd.

Completed

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Japan
AbbVie
Genentech, Inc.

Completed

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Japan
Otsuka Pharmaceutical Co., Ltd.
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Taiwan, Korea, Republic of, Japan
AbbVie

Completed

A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

Japan
Daiichi Sankyo Co., Ltd.
Daiichi Sankyo, Inc.

Completed

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Leukemia, Myeloid, Acute

Japan
Amgen

Terminated

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States, Korea, Republic of, Australia, Japan, Germany, Canada
Gilead Sciences

Terminated

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults (Japanese AML)

Acute Myeloid Leukemia | Hematologic Malignancy

Japan
Kanto CML Study Group
Epidemiological and Clinical Research Information Network

Completed

A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib (CMR-CML)

Chronic Myeloid Leukemia

Japan
Kanto CML Study Group

Unknown

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Myelogenous Leukemia, Chronic, Chronic Phase

Japan
Kanto CML Study Group
Epidemiological and Clinical Research Information Network

Completed

A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Japan
Astellas Pharma Inc

Active, not recruiting

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Acute Myeloid Leukemia | FLT3-mutated Acute Myeloid Leukemia

Japan, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Acute Myeloid Leukemia

Japan, United States
Novartis Pharmaceuticals

Completed

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Acute Myeloid Leukemia

Japan, Taiwan, Hong Kong, Thailand, Korea, Republic of, Russian Federation, Vietnam
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Astex Pharmaceuticals, Inc.

Terminated

Guadecitabine Extension Study

Acute Myeloid Leukemia | Myeloid Dysplastic Syndrome

United States, Taiwan, Korea, Republic of, Canada, Spain, Japan, Italy, Austria, Denmark
AbbVie

Active, not recruiting

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Acute Myeloid Leukemia (AML)

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Ireland, Japan, Korea, Republic of, Mexico, New Zealand, Norway, Puerto Rico, Russian Federation, South Africa, Spain, T... and more
Ariad Pharmaceuticals

Completed

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Japan
Novartis Pharmaceuticals

Recruiting

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

FLT3-mutated Acute Myeloid Leukemia

Korea, Republic of, Germany, Italy, Turkey, Czechia, Jordan, Slovenia, Austria, Poland, Japan, Russian Federation, United States, Greece
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Leukemia, Myeloid, Acute

United States, Spain, Korea, Republic of, Taiwan, Australia, Canada, Denmark, Hungary, Japan, Finland, Italy, Serbia, Czechia, France, Germany, Sweden, Netherlands, Poland, Russian Federation, Austria, United Kingdom, Romania, Belgium, Bulgar...
Bristol-Myers Squibb

Terminated

An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

Leukemia

Taiwan, United States, Brazil, Japan, Italy, Korea, Republic of, Canada, China, Israel, Romania
AstraZeneca

Completed

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients (SPARK-AML1)

Acute Myeloid Leukemia

United States, Italy, United Kingdom, Romania, Japan, Australia, Germany, Spain, France

Clinical Trials on Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations